SUBSCRIBE
SUBSCRIBE
News   FDA

Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial

May 23, 2008 | 
1 min read
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture.
FDA Approvals
MORE ON THIS TOPIC
A 3D rendering of white ceramic mortar and pestle, green medical cross emblem is affixed to the front of bowl. It represents the mixing and grinding raw ingredients.
Manufacturing
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
October 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Staying ahead of your competitors. Accelerated development of the company. Innovation vision. Customized solution. Unique skills. Red paper plane and whites. 3d render
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
 · 
4 min read
 · 
Heather McKenzie
3d pharmaceutical world icon with included clipping path.
Opinion
Biotechs going to market alone must learn to go global
October 28, 2026
 · 
3 min read
 · 
Paul Bridges